Jump to content

Search the Community

Showing results for tags 'lung cancer'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • WELCOME NEW MEMBERS!
    • INTRODUCE YOURSELF!
  • STORIES OF SURVIVORSHIP
    • SHARE YOUR LUNG CANCER STORY
  • DISCUSSION FORUMS
    • GENERAL
    • LC SURVIVORS
    • NSCLC GROUP
    • SCLC GROUP
    • LUNG CANCER MUTATIONS
    • IMMUNOTHERAPY
    • CAREGIVER RESOURCE CENTER
    • PALLIATIVE CARE
  • LUNG CANCER Q & A
    • LUNG CANCER NAVIGATOR
    • LUNG CANCER 101
  • NEWS / ADVOCACY
    • LUNG CANCER IN THE NEWS
    • CLINICAL TRIALS
    • FOUNDATION NEWS
    • ADVOCACY
    • CONFERENCES
  • LIVING WELL
    • HEALTHY LIVING / RECIPES
    • HOPE
    • JUST FOR FUN
  • SUPPORT / GROUPS
    • SUPPORT RESOURCES
    • SUPPORT GROUPS
  • GRIEF / RESOURCES
    • GRIEF
  • ABOUT THIS MESSAGE BOARD
    • FEATURES AND SUPPORT
    • TERMS OF USE

Blogs

  • An Advocate's Perspective
  • Cheryncp123's Blog
  • Lung Cancer Stories
  • PeggieH
  • Stay The Course
  • Stage IV Treatment With S.B.R.T.
  • Caregivers Connection
  • Spree
  • Volunteer Voices

Calendars

There are no results to display.


Found 123 results

  1. Patients' Gray Hair Turns Dark After Immunotherapy for Lung Cancer A surprising side effect of lung cancer treatment is turning heads. BY MINDY WAIZER Cancer treatments can have some terrible side effects. But one recent immunotherapy treatment for lung cancer has turned up a surprising — and not unwelcome — result. The patients’ gray hair turned significantly darker. The study, which was published in JAMA Dermatology, examined 14 patients who have non-small cell lung cancer (NSCLC) and were receiving immunotherapy treatments including one of the following agents: Opdivo (nivolumab), Keytruda (pembrolizumab) or Tecentriq (atezolizumab) at a hospital in Spain. Adverse effects of these kinds of treatments are likely to include cutaneous toxic side effects or dermatological problems, so the patients were being monitored by dermatologists. What doctors didn’t expect to see was that over the course of the treatment, the patients’ hair returned to youthful-looking, darker shades — the shades the patients’ hair had been before their hair turned gray. The average age of the patients was 65. Hair repigmentation is very rare. It has been reported before in relation to drugs such as Thalomid, for example, but it has never before been reported in relation to immunotherapy treatment for lung cancer. The reason for the darkening of patients’ hair color in these cases is still unclear. The number of patients in this study is small, and of course, more studies must be conducted. “This was totally unexpected, so it was exciting,” Noelia Rivera, M.D., dermatologist, Department of Dermatology, Hospital Universitari Germans Trias i Pujol, one of the authors of the study, said in an interview with CURE. “The high rates of good response to therapy in these patients was also an exciting finding. We are surprised at the results, and we are encouraged to keep on with the study,” she said. Thirteen of the 14 patients responded well to the immunotherapy treatment, reporting either partial or fully stable disease states. One had to stop the therapy after four cycles of treatment because of a life-threatening progression of the disease. The dual, positive implications of this study could be far-reaching. First, of course, it is good news for many patients with lung cancer, who may be able to benefit from these effective therapies. Second: just imagine if researchers could isolate the method for turning back the clock on graying hair. A whole new wave of age-defying hair solutions could be born. Rivera urges a cautious approach to the news of these patients’ hair repigmentation. “A lot of research is yet required, first to come up with a study, and after that, to get funding to develop the project,” she said. http://www.curetoday.com/articles/patients-gray-hair-turns-dark-after-immunotherapy-for-lung-cancer
  2. Call for Keytruda in NZ

    http://gisborneherald.co.nz/localnews/2941654-135/call-for-keytruda-drug-for-lung WAITING FOR GOOD NEWS. Cancer patient Alain Jorion is hoping Keytruda will be funded for New Zealanders battling lung cancer. HIGH-profile Gisborne fisherman Alain Jorion is calling for the “wonder drug” Keytruda to be funded for lung cancer patients. “It is my one and only hope,’’ the cancer patient said. Last year Keytruda, after a much-publicised public campaign, was funded by Pharmac, but for people with advanced stage 4 and 5 melanoma only. Mr Jorion and other lung cancer patients around the country are now calling for the drug to be funded for them. “Without funding, it costs $150,000 and would be administered privately in Auckland,” Mr Jorion said. “Amazingly, Keytruda is administered in Gisborne Hospital and funded, but for advanced melanoma.” Mr Jorion said funding Keytruda was for the potential benefit of thousands of New Zealanders who have or would get lung cancer in the future. “After all, it is our greatest cancer killer. The story of Keytruda can be a great story.” A study presented to Pharmac said one in three patients treated with the drug have their tumours shrink or disappear completely. The drug is administered intravenously every three weeks. Keytruda is an immunotherapy drug, which stimulates the body’s immune system to fight cancer cells. Known generically as Pembrolizumab, it was approved by Medsafe this year as a first treatment for lung cancer patients who have the PD-L1 expression of non-small-cell lung cancer (NSCLC) (PD-L1 is a protein expressed by cancer cells to evade the immune system.) The drug’s manufacturer, Merck Sharp and Dohme Limited (MSD), are seeking Pharmac funding, but it is not clear how long that will take. May be a year Mr Jorion believes it might take a year, while friends and a health professional have told him it might be sooner. Paul Smith, MSD New Zealand director, said the Keytruda registration “has the potential to transform the way lung cancer is treated in New Zealand” “Clinical trial results have been so compelling that trial investigators believe Keytruda should replace platinum-based chemotherapy to become the new ‘Standard of Care’ for untreated advanced NSCLC. Philip Hope, chief executive of the Lung Foundation New Zealand, said,“I hope that this medicine will be made available on a funded basis to all New Zealanders with life-threatening lung cancer”. Lung cancer is diagnosed in about 2200 New Zealanders a year and more than 1600 people die from it each year. One in five people diagnosed with lung cancer, like Mr Jorion, have never smoked. Mr Jorion said he wanted to be involved in Keytruda trials. “I have to run with the trial as it’s my only hope really.” His oncologist describes him as “the perfect candidate’’ for the trial as a non-smoker who has not had chemotherapy”. “She said I was in pretty good nick. She will go back to Hamilton and send me the relevant paperwork to enter me into a trial. Trials are back on the agenda. She says this is her best recommendation for now for me.” Mr Jorion has another disappointing issue in that Dr William McCallum who has worked with cancer patients at Gisborne Hospital, Palmerston North Hospital and is curently supervising house surgeons and registrars at Dunedin Hospital and helping Otago University students, is having work visa and immigration issues. Patients using Keytruda He said Dr McCallum had evidence involving 2799 patients who used Keytruda for lung cancer. “He has worked extensively in America, Europe, New Zealand.” He loved Gisborne and would be a great asset to the country. Dr McCallum told the Herald he supported funding for Keytruda for NSCLC in New Zealand. “Although expensive, fortunately we are able to bargain for drug prices in New Zealand and that will make the cost significantly less than what it would be in the US. “Keytruda was originally brought on the market for melanoma but even though its original indication was for melanoma, studies were being done for its use in other cancers, particularly NSCLC. “It is now being studied for other types of cancers. I say that because it is important to know that many of the new immunotherapies are being used in various other cancers. “Keytruda is also now known to be more effective in NSCLC when used with classical chemotherapy. “This information came out of the recent world-wide oncology conference (ACOG) in Chicago in June. “It is important to remember that cancer is not ‘a’ or ‘one’ disease, rather, as we are finding out more every day, a disease that is a normal cell that has mutated, that unless stopped will grow without interference. “Now, more and more we are able to look at the specific genetic traits of these cells and find ways to stop them,’’ said Dr McCallum. Praise for Gisborne Hospital He had high words of praise for Gisborne Hospital. “When I worked there, I was very happy with what we could do there and I think we did a very good job and I think they still do. “The nurses and support staff are fantastic and the doctors I worked with were caring and capable. “I have stated that to folks in Gisborne who thought maybe it wasn’t such a great place, we can always improve, but we have nothing to apologise for.” Dr McCallum said he understood and agreed with controls that had to be placed on expensive drugs like Keytruda. “However, when one has a patient like Alain, a non-smoker and someone who has lived a very healthy lifestyle, then he is the ideal patient. “Alain is an excellent candidate for Keytruda and, I would argue chemotherapy, as he is chemotherapy naive and has been in complete remission until recently. “Alain is one of the kindest, gentle and smartest people that I know, and he is a great fisherman.”
  3. Here is the weekly clip report: Health “The Difference Between Small Cell and Non-Small Cell Lung Cancer” http://www.health.com/smoking/small-cell-lung-cancer-non-small-cell-lung-cancer Genetic Engineering & Biotechnology News “CRISPR Screen Identifies Top 100 Essential Genes for Cancer Immunotherapy” http://www.genengnews.com/gen-news-highlights/crispr-screen-identifies-top-100-essential-genes-for-cancer-immunotherapy/81254771 Healio “FDA Grants Orphan Drug Designation to Tesevatinib for EGFR-Mutated Non-Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{1be8c744-6be6-42fa-b024-6e12a8bd01f5}/fda-grants-orphan-drug-designation-to-tesevatinib-for-egfr--mutated-non-small-cell-lung-cancer Targeted Oncology “Combinations, Biomarkers Will Be Future Focus in Metastatic NSCLC, Expert Says” http://www.targetedonc.com/news/combinations-biomarkers-will-be-future-focus-in-metastatic-nsclc-expert-says Onc Live “Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLC” http://www.onclive.com/web-exclusives/sequencing-switches-intriguing-combos-being-debated-in-alk-nsclc U.S. News & World Report “Best Hospitals for Cancer” http://health.usnews.com/best-hospitals/rankings/cancer Health “7 Causes of Lung Cancer in Non-Smokers” http://www.health.com/smoking/causes-of-lung-cancer-non-smoker MIT Technology Review “Cancer Blood Tests Score Early Success” https://www.technologyreview.com/s/608601/cancer-blood-tests-score-early-success/ Cure “Expert Discusses Stem Cell Research and Personalizing Lung Cancer Care” http://www.curetoday.com/articles/expert-discusses-stem-cell-research-and-personalizing-lung-cancer-care OncLive “Molecular Targets Could Be Unraveled for Patients with Non-Driver NSCLC” http://www.onclive.com/web-exclusives/molecular-targets-could-be-unraveled-for-patients-with-nondriver-nsclc OncLive “Liquid Biopsies, NGS Expected to Become Standard in Lung Cancer” http://www.onclive.com/web-exclusives/liquid-biopsies-ngs-expected-to-become-standard-in-lung-cancer
  4. Hi, I was diagnosed with State IV lung cancer that spread to liver and lymph nods....I started chemo and got thru almost 2 cyles of abraxane/carboplatin and my count hit bottom so I've missed the last 2 weeks of chemo and my last cycle for this treatment....I've tried everything, they say eat healthy, but its not working or working very slowly. I go back on Monday to see if the t counts are good... I also since this started lost so much weight, I can't get past 89.5 lbs.....so try to eat healthy and gain weight....what a joke.....In the meantime, I've missed 2 weeks of treatment....It scares me.... Any fattening suggestions
  5. The research team at Tulane University is conducting an online survey of individuals with cancer histories. We are particularly interested in individuals with a history of lung cancer. The survey takes about 10 minutes and asks about people's beliefs about their health and healthcare, emotions and behaviors, and health history. We hope that the study will build knowledge that can help individuals with cancer to be more satisfied with their care. Here is a link to the survey http://tulanestudy.com his study has been approved by LUNGevity Foundation.
  6. Co-written by LUNGevity and Mesothelioma Cancer Alliance A recent shift in cancer treatments from traditional, aggressive, overarching methods to targeted therapies tailored to individual patients and their medical situation has produced a resurgence of research in immunotherapy as a cancer treatment including multiple FDA approvals in the last few years. Today we are it taking a moment to reflect on how immunotherapy has progressed over the last twenty years. Immunotherapy is nothing new and has been in use for more than a century, but its potential is often seen as a mystery. While the average person might not understand the finer intricacies of these rapidly developing treatments, patients and doctors alike are reaping the benefits. Immunotherapy is a type of treatment that is meant to boost the body’s own immune system to help identify and fight rogue pathogens and cells, including cancer cells. In some cases, treatments can help activate the body’s defenses to better equip a patient to fight off diseases more efficiently. In other instances, immunotherapy may provide the immune system with proteins it’s lacking. When cancer cells develop, they may send signals like a mask that deceives the patient’s body into recognizing them as normal, so the invading cells aren’t attacked. In other cases, a person’s immune system might notice the cancer cells are different, but still doesn’t attack them. To help combat this, medical researchers have developed drugs called immune checkpoint inhibitors to provide T cells—specialized immune cells—the ability to identify cancer cells and attack them. For example, cancer cells produce high amounts of a protein called PD-L1. This protein binds to T cells and blocks them from launching an attack against the cancer cells Immune checkpoint inhibitors that can block this connection have helped patients fight several types of cancer, including melanoma, some types of lung cancer, and head and neck cancers. Therapeutic cancer vaccines have also been developed in recent years in an attempt to boost the immune system to fight off infections or, like other forms of immunotherapy, attempts to spark an immune response to fight the cancer cells. The most well-known types of these vaccines are meant to prevent the HPV virus, which has been linked to several types of cancer, such as cervical and throat cancers. In most cases, however, the drugs have not been approved, although several cancer vaccines are currently being studied in clinical trials. The main drawback of these types of vaccines is that unlike regular vaccines, which train the body to attack viruses by using weakened versions of them, therapeutic cancer vaccines attempt to encourage the body’s immune system to attack a disease that’s already in the body. Lung cancer describes many different types of cancer that start in the lung or related structures. There are two main types of lung cancer: non-small cell (NSCLC) and small cell lung cancer (SCLC). Currently, immune checkpoint inhibitors are available for a subset of advanced-stage NSCLC cancer patients. For those NSCLC patients whose tumors produce high amounts of PD-L1 protein, pembrolizumab, an immunotherapy drug federally approved to treat melanoma and non-small cell lung cancer, is available both in the first-line setting, as well as for those patients who have progressed on chemotherapy. A combination of chemotherapy and pembrolizumab has been shown to work in adenocarcinoma (a subtype of NSCLC) patients whose tumors don’t make PD-L1 protein. Two other drugs, nivolumab and atezolizumab, are available for advanced-stage NSCLC patients in the second-line setting, irrespective of how much PD-L1 protein is made by their tumors. Currently, immunotherapy either as monotherapy or in combination, are ongoing in both NSCLC and SCLC. Readout of these trials will determine standard of care of advanced-stage lung cancer patients. For those battling mesothelioma, a rare cancer often found in the lining of the lung and directly linked to asbestos exposure, immunotherapy could be a new tool patients can use to fight their cancer and extend their lives. Currently, immunotherapy for mesothelioma is showing promise in early clinical trials, namely with pembrolizumab. If the trials continue to present promising results, the treatment could eventually be FDA-approved for mesothelioma, giving doctors and patients an opportunity to more effectively target and treat this aggressive disease. Clinical trials are paramount to furthering our knowledge and generating the best results for current patients and those who may be at risk of developing cancer in the coming years. The advent of the National Cancer Moonshot has streamlined the clinical trial process, which according to the National Cancer Institute has drawn in about 5 percent of cancer patients into trials each year. By making it easier to find and join these important trials, hopefully more patients will get involved and eventually send the valuable information they provide as feedback to their doctors and medical researchers, which ultimately benefits current and future patients. Mesothelioma is only one cancer benefiting from more access to clinical trials, but the overall development of immunotherapy is giving the medical community hope for an eventual cure by better harnessing the body’s own defenses. While immunotherapy is currently being used as both a stand-alone treatment and as part of a combination treatment method with surgery, radiation and/or chemotherapy, one thought is that one day it could replace traditional methods entirely. With that said, we must move along with cautious optimism—there are still many unknowns and a long road of research ahead. Some cancers and even specific patients have not responded as well to current immunotherapy treatment methods. Researchers are hoping to discover more prognostic biomarkers that will better predict which patients will respond well to the treatment based on their cancer type and own gene set. There is still much research to do on improving side effects of immunotherapy as well, which have many factors that affect severity including the patient's health and the stage and type of cancer. As more studies are conducted and research is completed, scientists and researchers hope immunotherapy becomes even more effective at treating not only lung cancer and mesothelioma, but also patients across all cancers. Immunotherapy isn’t a miracle cure for cancers, but it’s quickly becoming a valuable tool doctors and patients can use to extend their lives and raise their quality of life. Immunotherapy as we know it is still in its infancy, but has quickly become a shining star in the medical world. Patients are already reaping some of the benefits this type of treatment provides, and for those in clinical trials, the studies are offering them something intangible: hope. That’s something everyone can use, especially during such a trying and difficult time.
  7. Here is the weekly clip report: Healio “FDA Grants Breakthrough Therapy Designation to Imfinzi for Non-Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{ff2af53b-37fe-4249-8680-63b558b163a7}/fda-grants-breakthrough-therapy-designation-to-imfinzi-for-non-small-cell-lung-cancer Specialty Pharmacy Times “Concurrent Chemotherapy, High-Dose Proton Beam Radiotherapy Show Promise in Advanced Lung Cancer” https://www.specialtypharmacytimes.com/news/concurrent-chemotherapy-high-dose-proton-beam-radiotherapy-show-promise-in-advanced-lung-cancer Medscape “In Immunotherapy, Approved Biomarkers Pose Many Problems” http://www.medscape.com/viewarticle/883451 Times Leader “Dance Club Supports LUNGevity Foundation” http://timesleader.com/community-features/669953/dance-club-supports-lungevity-foundation-4 Cancer Therapy Advisor “Study Predicts Important Role for SABR in Treatment of Early-Stage NSCLC” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-sabr-treatment-important-role/article/678775/ U.S. News & World Report “Back Pain and Other Unusual Signs of Lung Cancer” http://health.usnews.com/health-care/patient-advice/articles/2017-08-01/back-pain-and-other-unusual-signs-of-lung-cancer New York Magazine “Here’s What Not to Say to Someone with Cancer” http://nymag.com/scienceofus/article/heres-what-not-to-say-to-someone-with-cancer.html Targeted Oncology “Options for Upfront Treatment of ALK-Rearranged NSCLC” http://www.targetedonc.com/case-based-peer-perspectives/lung-cancer/langer-alk-nsclc/options-for-upfront-treatment-of-alk-rearranged-nsclc Wicked Local – Scituate “Scituate Man Throws Out Red Sox Pitch and Raises Awareness for Lung Cancer” http://scituate.wickedlocal.com/news/20170803/scituate-man-throws-out-red-sox-pitch-and-raises-awareness-for-lung-cancer OncLive “FDA Grants Frontline Alectinib Priority Review for ALK-Positive NSCLC” http://www.onclive.com/web-exclusives/fda-grants-frontline-alectinib-priority-review-for-alkpositive-nsclc Cancer Network “Concurrent Chemo, Proton Therapy Promising in Advanced Lung Cancer” http://www.cancernetwork.com/news/concurrent-chemo-proton-therapy-promising-advanced-lung-cancer Specialty Pharmacy Times “FDA Grants Durvalumab Breakthrough Therapy Designation for Locally-Advanced Lung Cancer” https://www.specialtypharmacytimes.com/news/fda-grants-durvalumab-breakthrough-therapy-designation-for-locally-advanced-lung-cancer Everyday Health “Five Reasons to Be Optimistic About Lung Cancer” https://www.everydayhealth.com/lung-cancer/living-with/reasons-optimistic-about-lung-cancer/
  8. FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer South San Francisco, CA -- August 2, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Alecensa® (alectinib) as an initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. The FDA will make a decision on approval by November 30, 2017. “Phase III results showed Alecensa reduced the risk of disease worsening by more than half compared to the current standard of care and lowered the risk of tumors spreading to or growing in the brain by more than 80 percent,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We are working closely with the FDA to bring this medicine as an initial treatment for people with ALK-positive NSCLC as soon as possible.” This sNDA submission for Alecensa is based on results from the Phase III ALEX and Phase III J-ALEX studies. A Priority Review designation is granted to proposed medicines that, if approved, the FDA has determined to have the potential to provide a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious disease. Alecensa received Breakthrough Therapy Designation from the FDA in September 2016 for the treatment of adults with advanced ALK-positive NSCLC who have not received prior treatment with an ALK inhibitor. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases and to help ensure people have access to them through FDA approval as soon as possible. Breakthrough Therapy Designation was granted on the basis of the Phase III J-ALEX trial. Alecensa was granted accelerated approval by the FDA in December 2015 for the treatment of people with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. The ALEX study is part of the company’s commitment in the U.S. to convert the current accelerated approval of Alecensa in people with ALK-positive, metastatic NSCLC who have progressed on or are intolerant to crizotinib to a full approval as an initial treatment. Read the full press release here.
  9. Here is the weekly clip report: Patient Daily “FDA Approves AstraZeneca's Tagrisso for Treating Certain Forms of Lung Cancer” http://patientdaily.com/stories/511146319-fda-approves-astrazeneca-s-tagrisso-for-treating-certain-forms-of-lung-cancer Medical News Today “Small Cell Lung Cancer: Cause of Treatment Resistance Discovered” http://www.medicalnewstoday.com/articles/318547.php Medical Xpress “Breaking the Genetic Resistance of Lung Cancer and Melanoma” https://medicalxpress.com/news/2017-07-genetic-resistance-lung-cancer-melanoma.html CNBC “Google Parent Company Invested in a Hot Cancer-Testing Start-Up and Built It a Dedicated Lab” http://www.cnbc.com/2017/07/24/alphabet-verily-invests-in-freenome-builds-lab-on-google-campus.html Across America Patch “Increasing Hope for Some Patients With a Common Type of Lung Cancer” https://patch.com/us/across-america/increasing-hope-some-patients-common-type-lung-cancer Benzinga “Lung Cancer Mutation Consortium Finds Breast Cancer Driver, HER2, in 3 Percent of Lung Cancers” https://www.benzinga.com/pressreleases/17/07/p9833596/lung-cancer-mutation-consortium-finds-breast-cancer-driver-her2-in-3-pe Cure “Being a Sibling of a Cancer Patient” http://www.curetoday.com/community/kim-johnson/2017/07/being-a-sibling-of-a-cancer-patient
  10. Heather Hogan's Story

    I was 52, a wife, mom and teacher when diagnosed with stage 3a NSC Adenocarcinoma lung cancer in September 2012. I had no symptoms and did not fit the criteria of a lung cancer candidate. An observant radiologist had noticed a small shadow in my lower right lobe when viewing an unrelated abdominal scan in 2010. Because I didn’t fit any of the LC criteria, no specialist or surgeon thought that it would be lung cancer. They adopted a “wait and see” plan using two six-month scans and then moved to a one-year scan at which that point indicated that my “nothing” spot had in fact grown and was probably lung cancer. My world had been turned upside down. I quickly had surgery to remove my bottom right lobe and several lymph nodes. Unfortunately, cancer was found in the lymph nodes and the tumor. This led to four rounds of chemotherapy (Cisplatin and Navelbine) and 25 treatments of radiation along with all the mental and physical issues that many people can only imagine. Cancer can be a very lonely disease even when you have a ton of support. I couldn’t find survivors in my area so I began searching out on-line groups that I could communicate with about my disease. This is where I discovered LUNGevity! The members of this group and all those associated with the organization wrapped their cyber arms around me and welcomed me into their world. This was literally a life-saving experience for me and continues to be part of my daily communication. Two years ago, people in the group began speaking about the National HOPE Summit in Washington, D.C. and how beneficial it was for both patients and caregivers. Because I am Canadian, I inquired as to whether my husband and I could attend. I was told of course we could! My husband and I attended HOPE Summit and that experience has changed my life. Meeting other survivors and hearing from physicians and researchers empowered me to return to my own country and begin asking questions about lung cancer research and most importantly, begin my work as a lung cancer advocate. The Summit allowed me to meet so many people who are advocates not only for their own health but also for lung cancer research and advocacy work. These people meet with politicians, organize, and participate in lung cancer fundraisers and teach so many of us about treatment options. Although Canada does not have as large a network, there is a small group of us who have been empowered to meet with politicians, educate and support others with the disease and spread the word about early lung cancer diagnosis, all because of our experience at a LUNGevity HOPE Summit. Education is power but knowing you are part of a strong, supportive, and knowledgeable group of individuals is invaluable. Thank you LUNGevity!
  11. Here is the weekly clip report: WSMV-TV “Knoxville Girl's Lemonade Stand Raises More Than $4K for Mom's Cancer Fight” http://www.wsmv.com/story/35893378/knoxville-girls-lemonade-stand-raises-more-than-4k-for-moms-cancer-fight PR Newswire “LUNGevity Foundation and 32 Cancer-Related Patient Advocacy and Professional Organizations Jointly Oppose Senate's Revised BCRA” http://www.prnewswire.com/news-releases/lungevity-foundation-and-32-cancer-related-patient-advocacy-and-professional-organizations-jointly-oppose-senates-revised-bcra-300489076.html The Commercial Appeal (USA Today) “New Baptist Project Catches Lung Cancer in Early Stages” http://www.commercialappeal.com/story/news/2017/07/17/new-baptist-project-catches-lung-cancer-early-stages/469710001/ Healio “Genomic Testing for Non-Small Cell Lung Cancer Underused in Community-Based Practices” https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{f5d98ce8-8ab1-4d4c-b52e-c85b4ee1533f}/genomic-testing-for-non-small-cell-lung-cancer-underused-in-community-based-practices Midland Daily News “Breakthrough Lung Cancer Detection Equipment Now Available Locally” http://www.ourmidland.com/news/article/Breakthrough-lung-cancer-detection-equipment-now-11291920.php Medical Xpress “Cause of Chemo Resistance in Small Cell Lung Cancer Discovered” https://medicalxpress.com/news/2017-07-chemoresistance-small-cell-lung-cancer.html American Journal of Managed Care “LDH Levels Could Predict irAEs Associated With Checkpoint Inhibition and Radiotherapy in Lung Cancer” http://www.ajmc.com/journals/evidence-based-oncology/2017/July-2017/LDH-Levels-Could-Predict-irAEs-Associated-With-Checkpoint-Inhibition-and-Radiotherapy-in-Lung-Cancer US News “Understanding Targeted Therapies for Lung Cancer” http://health.usnews.com/health-care/patient-advice/articles/2017-07-18/understanding-targeted-therapies-for-lung-cancer Healio “Maintenance Pembrolizumab Benefits Certain Patients with Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{748e9e43-ff90-44ef-af7b-a53722107e65}/maintenance-pembrolizumab-benefits-certain-patients-with-small-cell-lung-cancer Cure Today “Persisting Gaps in Cancer Care Affect Patient Outcomes” http://www.curetoday.com/advocacy/CancerSupportC/persisting-gaps-in-cancer-care-affect-patient-outcomes Oncology Practice “Immune Signature Shows Good Prognostic Performance in Early-Stage NSCLC” http://www.mdedge.com/oncologypractice/article/142757/lung-cancer/immune-signature-shows-good-prognostic-performance-early MedScape “ASCO Addresses High Cost of Cancer Drugs” http://www.medscape.com/viewarticle/883115
  12. Thirteen Years; Thirteen Toes!

    Today we celebrate 13 years of surviving NSCLC. I'm borrowing three toes from Martha, my wife and caregiver extraordinaire, who deserves most of the credit for my continued life. Martha did the heavy lifting during treatment, asking the right questions at the right time, and prodding my medical team with just the right touch. By comparison, I was at wit's end during my nearly 4 years of continuous treatment. Doctors McK (GP), H (Oncologist) and C (Thoracic Surgeon) also deserve a lion's share of credit. Collectively, they share a trait that distinguishes them from the rest of medical community -- they treat people, not patients. The red toenail painting tradition was started by a Dr. Phillip Berman, radiologist and never smoker, who was diagnosed with Stage IV NSCLC. In an early Internet cancer website he founded, RedToeNail.org, he vowed to paint a toenail red for each year he survived what he called "this nastiness." He painted 5 before passing but taught me a great deal about living with lung cancer. During treatment, he was playing with his children, exercising, interacting with friends, and finding something to enjoy every day. In other words, he embraced the life he had and lived every day reveling in the joy he discovered. His lesson -- those who choose treatment choose life and the important thing is to do something with the life you have. I pass his powerfully evocative message to you. If you suffer with lung cancer then resolve to live every day and find something to enjoy. Realize that if I can live, so can you. Paint your toenails red! Stay the course. Tom
  13. Jan Poulsen's Story

    It came as quite a surprise when I was first diagnosed with Stage 3 lung cancer in 2007. It was an even bigger shock to learn that my lung cancer was caused by exposure to high levels of radon gas in my own home. I want to keep sharing my story with the hope that it might prevent others from getting lung cancer from radon gas. My husband and I did extensive renovations on our house to turn it into our dream home. About five years later, I developed a nagging cough. I went to the doctor, who sent me for a CT scan. The scan showed a mass in my right lung, so we scheduled an appointment with a pulmonologist to have a biopsy. The doctor who performed the biopsy called to tell me that I had lung cancer and that it was inoperable. He told me that I had four months to live. My husband had just returned from a trip to Africa and my mother was staying with us while she recovered from surgery. I turned on the T.V. and Jordin Sparks was singing, “This is My Now” and it just hit me that “you can sit here and feel sorry for yourself or you can fight it.” It’s crazy how the universe works. Shortly after I was diagnosed, we had our home tested for radon gas, the second leading cause of lung cancer. The test showed levels that were 6-times the EPA recommended action level. I had my right lung removed and underwent 5 weeks of radiation and 4 months of chemotherapy. I started to gain my strength back and started looking for a lung cancer community. In the beginning, there was very little information about lung cancer. I couldn’t find anyone to talk to. Then my daughter found out about LUNGevity and a walk they were holding in Manhatten Beach, California, called Breathe Deep Los Angeles. She said we should go there on a girls’ trip. Who wouldn't want to go to the beach after dealing with lung cancer treatment? My first Breathe Deep experience was so inspirational. There were over 350 people walking whose lives had somehow been touched by lung cancer. I’d never been to anything like that and there was nothing like that where I lived near Salt Lake City. When we got home, my other daughter said, “Why don’t we start one here?” So we held our first Breathe Deep Salt Lake City in 2012. I remained cancer free for 6 years, then in 2014 they found a fist-sized tumor in the front of my brain and a smaller tumor in the back which was metastasized lung cancer. They were able to remove those tumors and I went back into remission until that December, when they found 6 more brain tumors. I underwent surgeries to remove those, and then in January 2015, I started on a new chemo pill that I take orally. This treatment has worked very well for me and now there are four more on the market that would work just as well or better if this one stopped working. This is why I am so passionate to raise funds for lung cancer research. I am living proof that it works. The new treatments are so effective and amazing, but researchers need funding to find a cure. Lung Cancer research receives the least amount of federal funding of all types of cancer, yet it is the deadliest. I feel it is so important to raise funds to improve outcomes for lung cancer patients. I think the most rewarding thing about being a Breathe Deep event coordinator is to see people coming back year after year because they know it’s a good cause. It makes you realize how many people care about health and our lungs. The more people you talk to, the more you find that they have a connection to lung cancer, whether it’s a family member or friend. In addition to raising funds and awareness, we try to provide information at our event. We have speakers who talk about new discoveries in lung cancer treatment and radon. In fact, just because we’ve been raising awareness, a lot of the real estate agents are on board with getting homes they sell tested for radon gas. A local organization that does radon testing is even donating $20 of every radon test they do to LUNGevity. They’re promoting the walk to all of the real estate agencies that they work with. It’s amazing how generous people are. At first, I thought I can’t go around asking for free stuff. But I’ve found that people are willing to help! I really feel like the grassroots is the way to reach people. I’ve had more success talking to people one-on-one. We’ve done some women’s groups and I’ve spoken at classes on Radon. I also worked with a social worker to put together a lung cancer support group. The online groups are great, but sometimes, you just really need to talk so somebody in person. In addition to LUNGevity, I’ve also been doing a lot with the Utah Radon coalition. And I’m going to be speaking at the international radon convention in New Orleans in October. I want to show that there’s a face to lung cancer caused by radon gas. If it can happen to me, it can happen to anyone. Preventing lung cancer is so much easier and less costly than treating lung cancer.
  14. Here is the weekly clip report: Healio “Brigatinib Confers Positive Outcomes in ALK-Positive Non-Small Cell Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{d8bfdb5c-8523-4a48-b4c7-555cb37b3c54}/brigatinib-confers-positive-outcomes-in-alk-positive-nonsmall-cell-lung-cancer CNBC “Roche Unveils Advancements in Breast and Lung Cancer Drugs” http://www.cnbc.com/video/2017/06/05/roche-unveils-advancements-in-breast-and-lung-cancer-drugs.html Medical Xpress “Greater Access to Genetic Testing Needed for Cancer Diagnosis and Treatment” https://medicalxpress.com/news/2017-07-greater-access-genetic-cancer-diagnosis.html Healio “Ceritinib Demonstrates Activity in ROS1-Positive Non-Small Cell Lung Cancer https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{217b896c-1abb-4689-a58c-31ae7c608d5c}/ceritinib-demonstrates-activity-in-ros1-positive-nonsmall-cell-lung-cancer Cancer Network “Is one immunotherapy for lung cancer better than the rest?” http://www.cancernetwork.com/videos-lung-cancer/one-immunotherapy-lung-cancer-better-rest Farragut Press “Lemons for LUNGevity” http://www.farragutpress.com/articles/2017/07/6353.php Cure “Examining the Role of Blood-Based Biomarkers in Lung Cancer” http://www.curetoday.com/articles/examining-the-role-of-bloodbased-biomarkers-in-lung-cancer Cancer Therapy Advisor “Proton-Beam Therapy May Be Effective for Limited-Stage Small-Cell Lung Cancer” http://www.cancertherapyadvisor.com/lung-cancer/proton-beam-therapy-effective-small-cell-lung-cancer/article/673364/ Specialty Pharmacy Times “Measuring T Cell Levels May Help Identify Patient Response to Immunotherapy” https://www.specialtypharmacytimes.com/news/measuring-t-cell-levels-may-help-identify-patient-response-to-immunotherapy Specialty Pharmacy Times “Nanotechnology Could Change the Future of Disease Treatment” https://www.specialtypharmacytimes.com/news/nanotechnology-could-change-the-future-of-disease-treatment KUSA-TV “Idris Elba Opens Up About Father's Death and Going Through a Midlife Crisis: 'I Wasn't Even Living’” http://www.9news.com/entertainment/entertainment-tonight/idris-elba-opens-up-about-fathers-death-and-going-through-a-midlife-crisis-i-wasnt-even-living/454711270
  15. The Down Low on Low Dose

    The other day, in conversation with a newly minted medical school graduate, he told me low-dose computed tomography (LDCT) was dangerous. Dangerous! If LDCT is dangerous, what is late discovery of lung cancer? He nearly fainted when I told him I had perhaps more than 40 CT scans in my treatment history, telling me I was a candidate for radiation induced cancer. It didn’t seem to register that I was a candidate for extinction by lung cancer. We are told the only effective way of treating our disease is early discovery. Few dispute this point. Why then would the Center for Medicare & Medicaid Services (CMS) want to reduce reimbursement for low-dose computed tomography (LDCT) screening by more than 40 percent? The Society of Thoracic Surgeons is concerned calling LDCT a “game changer in the battle against lung cancer.” Then I read: “Family physicians lack sufficient knowledge about recommendations for LDCT." Moreover, Doctors Patz and Chen, professors of radiology at Duke, say: “Not screening patients annually could save millions in health care costs and spare patients the radiation exposure and downstream effects of false positive screenings.” Something is very wrong. We have an effective tool for early discovery of life-threatening disease when not discovered early, and there is a campaign mounted against using it. CMS is a federal government-funded agency. In government programs there is a big difference between savings (cash you can put in the bank) and avoidance (cash spent elsewhere). CMS money is appropriated in broad categories. Once appropriated, fiscal managers move money around to address other needs or requirements. Appropriated federal funds are almost never returned to the Treasury. So the reduced funding for LDCT will be a bill payer for some other CMS program. No money is saved; it is spent on something else. Further, when making a valid cost avoidance argument, one must identify all cost. For example, the professors of radiology predicting savings for reduced screening do not identify the millions of dollars of increased cost for treating late-stage-diagnosed lung cancer. A cost avoided almost always results in cost added somewhere else, and without disclosing added burden, professionals are making very unprofessional arguments. Lastly, and most importantly, no one advocating reducing LDCT is considering the most important impact—suffering. There is a vast amount with late-stage diagnosis. Suffering affects more than the lung cancer survivor; it devastates families. While real and detrimental, suffering defies quantification in dollars. Several hundreds-of-thousands of us in the United States will suffer a late-stage lung cancer diagnosis this year. LDCT can eliminate some of this. In this light, it is hard to understand the assault against using LDCT to find, fix, and finish lung cancer! Stay the course.
  16. Here is the weekly clip report: Genetic Engineering and Biotechnology News “Discovery of New Immune Cell May Improve Treatment of Lung Cancer Patients” http://www.genengnews.com/gen-news-highlights/discovery-of-new-immune-cell-may-improve-treatment-of-lung-cancer-patients/81254527 Specialty Pharmacy Times “Alectinib Slashes Risk of Disease Progression or Death by Half in Patients with NSCLC” https://www.specialtypharmacytimes.com/news/alectinib-slashes-risk-of-disease-progression-or-death-by-half-in-patients-with-nsclc Cancer Network “ASTRO Issued New Guideline on Use of SBRT in Early-Stage Lung Cancer” http://www.cancernetwork.com/news/astro-issued-new-guideline-use-sbrt-early-stage-lung-cancer Radiology Business “Dozens of House Members Caution against Further Cuts to Lung Screening Reimbursement” http://www.radiologybusiness.com/topics/policy/dozens-house-members-caution-against-further-cuts-lung-screening-reimbursement Targeted Oncology “The Debate over Upfront Use of Newer Targeted Agents in NSCLC” http://www.targetedonc.com/publications/targeted-therapy-news/2017/June-2017/the-debate-over-upfront-use-of-newer-targeted-agents-in-nsclc Genome Web “In Efforts to Ramp Up Adoption of Liquid Biopsies, Lung Cancer Becomes Proving Ground” https://www.genomeweb.com/molecular-diagnostics/efforts-ramp-adoption-liquid-biopsies-lung-cancer-becomes-proving-ground Mayo Clinic News Network “Blood-Based Lung Cancer Test Shows Promise: Mayo Clinic Radio Health Minute” http://newsnetwork.mayoclinic.org/discussion/blood-based-lung-cancer-test-shows-promise-mayo-clinic-radio-health-minute/ Cancer Network “Atezolizumab Active in Advanced Lung Cancer, PD-L1 Predicts Response” http://www.cancernetwork.com/lung-cancer/atezolizumab-active-advanced-lung-cancer-pd-l1-predicts-response Harvard Business Review “New Approach to Safely Sharing Cancer Patients’ Data” https://hbr.org/2017/06/a-new-approach-to-safely-sharing-cancer-patients-data Cancer Therapy Advisor “Once-Daily Radiotherapy Not Superior to Twice-Daily in SCLC” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-sclc-radiotherapy-superior-twice-daily/article/670091/ Medical Xpress “Catching Cancer Earlier—a New Frontier for Early Detection Research” https://medicalxpress.com/news/2017-06-cancer-earliera-frontier-early.html Lung Cancer News Today “Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage” https://lungcancernewstoday.com/2017/06/22/entinostat-keytruda-clinical-trial-nsclc-proceed-next-stage/ Medical Xpress “First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients” https://medicalxpress.com/news/2017-06-first-line-immunotherapy-treatment-survival-subset.html PR Newswire “FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies” http://www.prnewswire.com/news-releases/fda-approves-first-companion-diagnostic-test-to-simultaneously-screen-for-multiple-non-small-cell-lung-cancer-therapies-300478690.html Cure Today “Combination Approved for BRAF-Positive Lung Cancer” http://www.curetoday.com/articles/combination-approved-for-braf-positive-lung-cancer Healio “10 Updates in Immunotherapy Research” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{4f336a9e-848e-49d8-8fe1-a43d04bbce72}/10-updates-in-immunotherapy-research
  17. Permission to Feel

    I noticed something recently at the in-person support group I facilitate. Caregivers in my group didn't speak up about issues or feelings unless the facilitator or group leader mentioned them first. "Like Jan said, I have feelings of ____ too." After the third time, it occured to me that caregivers are either waiting to have their feelings validated by someone else or didn't realize they had been feeling those feelings. I remember being a caregiver for my father and how all-encompassing that was. Nothing else mattered to me at the time. Everything was about my dad's cancer, his feelings, his happiness, his peace and comfort. I don't think I got more than 2-3 hours of sleep a night during those 11 months- there was just so much to do! I completely lost myself and any sense of "me" during my caregiving. I would never consider taking time for myself, taking a break or openly expressing my frustrations and concerns- that would be selfish- afterall, I wasn't the one in treatment with cancer. I wasn't the one fighting for my life, right? If given the opportunity then, would I have taken advantage of caregiver resources or support groups? Would I even know what I was feeling or how to describe it? Until we are able to have caregiver-only support groups in every community, how can we give caregivers the encouragement or "permission" to put a voice to what they are feeling? How do we as caregivers divorce ourselves from the guilt that accompanies self-care? Thoughts?
  18. Join Cancer Legal Resource Center tomorrow at 12:00 PM PT for the second webinar in our 2017 series. In this webinar, we will give an overview of the laws that provide protection in the workplace for those who are coping with a cancer diagnosis, including the Americans with Disabilities Act, state fair employment laws, the Family and Medical Leave Act, and other resources. Click here for more information, and to register online. This post was approved by LUNGevity.
  19. Allison Doan's Story

    Allison Doan has been on a long journey of self discovery, from a life of elite privilege to a brief time in federal prison, and then a battle with stage IV lung cancer. Through years of ups and downs, and finding forgiveness and strength she didn’t even realize that she possessed, Allison has remained determined to share a message of hope. Allison’s broken road has led her to a place of peace. She’s written an inspiring memoir, Bruised and Beautiful, which will be published later this month. By sharing her story, Allison hopes to inspire people that it’s possible to get through life’s hardships with love, faith, and trust. “I wanted to write the book when I was facing prison because I knew that I was going to take something horrible and scary and turn it into something good. I wanted to convey a message of hope that you can face anything with God on your side. When I started writing, I thought I’m going to end it here, and then the cancer struck,” says Allison. She describes her cancer diagnosis on her Caring Bridge site: “In early November 2014, I noticed a large lymph node on the right side of my neck. I was also having some pain with breathing and a dry cough. After some time had passed and no progress from antibiotics, my primary doctor ordered an ultrasound and several CT's which would reveal some concerns. The CT had shown 3 large lymph nodes in my chest (mediastinum area), 3 nodules in my lungs and 2 nodules in my thyroid gland. I was referred to an oncologist who ordered a biopsy on December 29. I was preparing myself for the news of possible lymphoma or squamous cell carcinoma according to what the doctor said. My doctor informed me that I have what looked to be medullary thyroid cancer a very rare form of thyroid cancer. A blood test was ordered to confirm this and a PET scan to see where the cancer might have spread. I began the arduous task of research to find those doctors that might have a specialty in this area. We decided to head to MD Anderson in Houston for a second opinion. After more testing and another biopsy it was confirmed that the cancer was actually coming from the lung. They diagnosed me with Stage IV neuroendocrine lung cancer which is incurable. After the shock and fear subsided I began to cling to my strong faith in our loving heavenly Father who holds me and this situation in His loving hands. Jeremiah 29:11 'For I know the plans I have for you sayeth the Lord, plans to prosper you and not to harm you, to give you a hope and a future.'” Realizing that her story wasn’t complete, Allison continued to write while undergoing treatment, hitting some roadblocks along the way. Allison says she “learned to navigate through the world of a cancer patient: days of normal, days of doctor visits, days of feeling great, and days of feeling crummy. Lung cancer is an up and down journey of new treatments. Then they stop working and you try something else.” Allison’s husband and care partner, Keith, has been by her side since the moment of her diagnosis. The two were married while she was undergoing treatment and planned their honeymoon in St. John in between clinical trials. Allison shared her story with country music artists Dave Fenley and Ray Johnston, who penned a song in her honor. The song, called Bruised and Beautiful (Alli’s Song), is full of grace and gratitude. It carries Allison’s powerful message of living each day to the fullest and trusting God. Part of proceeds from book and song will go to LUNGevity Foundation. LUNGevity was the first organization that Allison found when she started looking for online support after her diagnosis. The song Bruised and Beautiful is available for download on iTunes. Allison’s memoir of the same title, will be published in June 2017. In May, Allison entered hospice care to help with symptom relief and quality of life. She tells her family and friends that she’s staying “Allistrong” and that she’s humbled by the love, support, and encouragement she’s received. “Above all,” Allison says, “life is worth living.” Allison and her husband Keith, with their children Daniel, Peter, Megan, and Grant.
  20. MONDAY, JUNE 5 Reuters “Roche's Alecensa bests Pfizer's Xalkori in lung cancer trial” https://www.reuters.com/article/us-health-cancer-roche-pfizer-idUSKBN18W1HH Forbes “A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us” https://www.forbes.com/sites/matthewherper/2017/06/03/a-new-cancer-drug-helped-almost-everyone-who-took-it-almost-heres-what-it-teaches-us/#677ea9e6b25f The Telegraph (UK) “Cancer Patients Who Enter Their Symptoms into an App Live Longer than Expected, Study Suggests” http://www.telegraph.co.uk/science/2017/06/04/cancer-patients-enter-symptoms-app-live-longer-expected-study/ Patient Daily “FDA OKs Novartis’ Zykadia for Metastatic Lung Cancer Affecting the Brain”http://patientdaily.com/stories/511122036-fda-oks-novartis-zykadia-for-metastatic-lung-cancer-affecting-the-brain TUESDAY, JUNE 6 Drug Discovery & Development “ASCO 2017: Investigational Agent Improves Survival Outcomes for EGFR-Positive Lung Cancer” https://www.dddmag.com/article/2017/06/asco-2017-investigational-agent-improves-survival-outcomes-egfr-positive-lung-cancer The Washington Post “8 Things Doctors are Buzzing about at the Biggest Cancer Meeting” https://www.washingtonpost.com/news/to-your-health/wp/2017/06/06/7-attention-grabbing-topics-at-the-nations-biggest-cancer-meeting/?utm_term=.39f88e8f0ae0 WEDNESDAY, JUNE 7 Fannin Sentinel “Lungevity: Shining Light on the Invisible Disease” http://fanninsentinel.news/?p=7581 PR Newswire “Julie R. Brahmer, MD., MSc, is recognized by Continental Who's Who” http://www.prnewswire.com/news-releases/julie-r-brahmer-md-msc-is-recognized-by-continental-whos-who-300469906.html Healio “Pembrolizumab Reduces Need for Second-Line Therapy in Advanced NSCLC” http://www.healio.com/hematology-oncology/lung-cancer/news/online/{7d9e7f9c-c66a-4f06-9ab3-e95da959cad5}/pembrolizumab-reduces-need-for-second-line-therapy-in-advanced-nsclc ASCO Daily News “Studies Explore Targeted Therapies in Lung Cancer” https://am.asco.org/studies-explore-targeted-therapies-lung-cancer THURSDAY, JUNE 8 The New York Times “Cancer Drug Proves to Be Effective Against Multiple Tumors” https://www.nytimes.com/2017/06/08/health/cancer-drug-keytruda-tumors.html?_r=0 The New York Times “When Your Personal War on Cancer Is Exhausting” https://www.nytimes.com/2017/06/08/well/live/when-your-personal-war-on-cancer-is-exhausting.html?_r=0 EurekAlert “Scientific Advances in Thoracic Oncology in 2016 Highlighted by the IASLC” https://www.eurekalert.org/pub_releases/2017-06/iaft-sai060817.php FRIDAY, JUNE 9 Healio “Primary NSCLC May Be Underdiagnosed Among Patients with Metastatic Renal Cell Carcinoma” http://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{97a56d74-d2e8-44d3-942a-7e8f636341b7}/primary-nsclc-may-be-underdiagnosed-among-patients-with-metastatic-renal-cell-carcinoma Cure Today “Expert Discusses the Future of EGFR+ and ALK+ Lung Cancer” http://www.curetoday.com/articles/expert-discusses-the-future-of-egfr-and-alk-lung-cancer USA Today “’How Long Have I Got?’: Why Many Cancer Patients Don’t Have Answers ” https://www.usatoday.com/story/news/2017/06/09/kaiser-how-long-have-got-doc-why-many-cancer-patients-dont-have-answers/102518488/
  21. Here is the weekly clip report: TUESDAY, MAY 30 Miami Herald “Using Your Immune System to Fight Cancer is Showing Significant Promise” http://www.miamiherald.com/living/health-fitness/article152969614.html Cancer Network “Certinib Gets First-Line FDA Approval ALK-Positive Lung Cancer” http://www.cancernetwork.com/lung-cancer/ceritinib-gets-first-line-fda-approval-alk-positive-lung-cancer WEDNESDAY, MAY 31 CHEST (American College of Chest Physicians) “What You Need to Know About Biopsies for Lung Cancer” http://www.chestnet.org/News/Blogs/CHEST-Thought-Leaders/2017/05/What-you-need-to-know-about-biopsies OncLive “Modern Biopsy Techniques Changing the Scope of Lung Cancer Diagnosis” http://www.onclive.com/web-exclusives/modern-biopsy-techniques-changing-the-scope-of-lung-cancer-diagnoses Reuters “Cancer Meeting to Provide Clues on Future Immunotherapy Combos” https://www.reuters.com/article/us-health-cancer-immunotherapy-idUSKBN18R1EA Genome Web “Vanderbilt Team Using Mass Spec to Research Cancer Immunotherapy” https://www.genomeweb.com/proteomics-protein-research/vanderbilt-team-using-mass-spec-research-cancer-immunotherapy THURSDAY, JUNE 1 Lung Cancer News Today “Trilaciclib Improves Chemo’s Effectiveness Against Small Cell Lung Cancer, Study Finds” https://lungcancernewstoday.com/2017/06/01/study-shows-combination-of-triliciclib-and-chemo-benefits-lung-cancer-patients/ PR Newswire “Roche Announces FDA Approval of Companion Diagnostic to Identify ALK-Positive Non-Small Cell Lung Cancer Patients” http://www.prnewswire.com/news-releases/roche-announces-fda-approval-of-companion-diagnostic-to-identify-alk-positive-non-small-cell-lung-cancer-patients-300466815.html Business Wire “Atreca, Inc., and Dana-Farber Cancer Institute Establish Broad Cancer Immunotherapy R&D Collaboration” http://www.businesswire.com/news/home/20170531005968/en/Atreca-Dana-Farber-Cancer-Institute-Establish-Broad-Cancer NBC News “More New Cancer Drugs Mean Higher Costs But Also Longer Lives” http://www.nbcnews.com/health/health-news/more-new-cancer-drugs-mean-higher-costs-also-longer-lives-n767156 FRIDAY, JUNE 2 Bloomberg “A Hot-Cancer Drug Race Keeps Getting More Crowded” https://www.bloomberg.com/news/articles/2017-06-02/immune-oncology-drug-trials-are-getting-crowded Business Insider “The FDA and a $1.2 Billion Startup Are Analyzing How Drugs Are Used After Approval – and It Could One Day Change How we Treat Cancer” http://www.businessinsider.com/flatiron-health-collaboration-with-fda-data-at-asco-2017-6 U.S. News & World Report “As Scientists Train the Immune System to Fight Cancer, Others Look to Combat Costs” https://www.usnews.com/news/healthcare-of-tomorrow/articles/2017-06-02/as-scientists-train-the-immune-system-to-fight-cancer-others-look-to-combat-costs
  22. MONDAY, MAY 22 USA Today “Hope Summit is Just that for Lung Cancer Survivors” https://www.usatoday.com/story/life/2017/05/22/hope-summit-just-lung-cancer-survivors/101710746/ Patient Daily “AstraZeneca Reports Positive Results in Trial Using Imfinzi in Stage III Non-Small Cell Lung Cancer Cases” http://patientdaily.com/stories/511116688-astrazeneca-reports-positive-results-in-trial-using-imfinzi-in-stage-iii-non-small-cell-lung-cancer-cases TUESDAY, MAY 23 Business Insider “The FDA just Took an Entirely New Approach Approving a Cancer Drug” http://www.businessinsider.com/fda-approves-cancer-drug-based-on-genetic-markers-2017-5 Clinical Oncology News “ASCO Report: Gefitinib beats Chemo After Surgery in NSCLC” http://www.clinicaloncology.com/Lung-Cancer/Article/05-17/ASCO-Report-Gefitinib-Beats-Chemo-After-Surgery-in-NSCLC-/41434 U.S. News & World Report “Advice for Lung Cancer Caregivers” http://health.usnews.com/health-care/patient-advice/articles/2017-05-23/advice-for-lung-cancer-caregivers WEDNESDAY, MAY 24 Medical Xpress “Using a Genetic Signature to Overcome Chemotherapy-Resistant Lung Cancer” https://medicalxpress.com/news/2017-05-genetic-signature-chemotherapy-resistant-lung-cancer.html Reuters “Brief – Onocyte Presents Positive Lung Cancer Blood Test Data at American Thoracic Society” https://www.reuters.com/article/brief-oncocyte-presents-positive-lung-ca-idUSFWN1IO0IS THURSDAY, MAY 25 Genome Web “OncoCyte Lung Cancer Test Validation Data Bodes Well for Launch This Year” https://www.genomeweb.com/molecular-diagnostics/oncocyte-lung-cancer-test-validation-data-bodes-well-launch-year PR Newswire “NCCN Awards Grants to Investigators at Member Institutions to Study Osimertinib in Lung Cancer” http://www.prnewswire.com/news-releases/nccn-awards-grants-to-investigators-at-member-institutions-to-study-osimertinib-in-lung-cancer-300463998.html FRIDAY, MAY 26 Cancer Therapy Advisor “Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-Associated Survival” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-radiotherapy-might-improve-immune-checkpoint-blockade-survival/article/664708/ Cure Today “FDA Approves Zykadia for Metastatic Non-Small Cell Lung Cancer” http://www.curetoday.com/articles/fda-approves-zykadia-for-metastatic-nonsmall-cell-lung-cancer Patient Daily “Gefitinib Shown to Delay Recurrence of Lung Cancer Following Surgery” http://patientdaily.com/stories/511119431-gefitinib-shown-to-delay-recurrence-of-lung-cancer-following-surgery The ASCO Post “The Ongoing Challenges of Lung Cancer Screening” http://www.ascopost.com/issues/may-25-2017/the-ongoing-challenges-of-lung-cancer-screening/ ASCO Daily News “Targeting RET Rearrangements in Non–Small Cell Lung Cancer” https://am.asco.org/targeting-ret-rearrangements-non-small-cell-lung-cancer
  23. MONDAY, MAY 15 Medscape “What’s New for Lung Cancer? Stay Tuned for ASCO 2017” http://www.medscape.com/viewarticle/879994 TUESDAY, MAY 16 Healio “Survivors of Hodgkin Lymphoma Have Increased Risk for Second Cancer” http://www.healio.com/hematology-oncology/lymphoma/news/in-the-journals/{099e0b29-8044-4d8c-8215-f0691027f7d8}/survivors-of-hodgkin-lymphoma--increased-risk-for-second-cancer Forbes “How AI and Deep Learning is now Used to Diagnose Cancer” https://www.forbes.com/sites/bernardmarr/2017/05/16/how-ai-and-deep-learning-is-now-used-to-diagnose-cancer/#45695214c783 WEDNESDAY, MAY 17 Medical Xpress “Brigatinib First to Offer Over 1-Year Control of ALK-Positive Lung Cancer Post-Crizotinib” https://medicalxpress.com/news/2017-05-brigatinib-year-alk-positive-lung-cancer.html U.S. News & World Report “Cancer Fatigue: So Tired by Treatment” http://health.usnews.com/health-care/patient-advice/articles/2017-05-17/cancer-fatigue-so-tired-by-treatment Boston Globe “Two MGH Doctors Offer Step-by-Step Advice for Living with Cancer” https://www.bostonglobe.com/magazine/2017/05/17/two-mgh-doctors-offer-step-step-advice-for-living-with-cancer/rC0eryFm4VbgffHQfsNLLJ/story.html THURSDAY, MAY 18 Reuters “Merck, Incyte Immunotherapy Combination Effective in Lung Cancer Study” http://www.reuters.com/article/health-cancer-merck-incyte-idUSL2N1IJ1QC Medical Xpress “Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer” https://medicalxpress.com/news/2017-05-therapy-recurrence-intermediate-stage-lung-cancer.html FRIDAY, MAY 19 Reuters “CHMP Backs Novartis's Zykadia for First-Line Use in Lung Cancer” http://www.reuters.com/article/us-novartis-zykadia-idUSKCN18F1FK News-Medical “Researchers Discover Novel Mechanism That Causes Malignant Pleural Effusion in Lung Cancer Patients” http://www.news-medical.net/news/20170519/Researchers-discover-novel-mechanism-that-causes-malignant-pleural-effusion-in-lung-cancer-patients.aspx
  24. Paige Black

    I was diagnosed in April 2017 with lung cancer (stage 4 adenocarcinoma with malignant pleural effusion). I celebrated my 47th birthday in May. My husband and I will celebrate our 22nd wedding anniversary in July. We have a 12 year old daughter. This is my second stage 4 cancer diagnosis. The first was shortly after my husband asked me to marry him. I was 23 years old and had stage 4 Hodgkins. I was treated with a combination MOPP ABVD regimen. My life was placed on pause while I took 24 treatments and tried to make a new normal. After 15 months of chemotherapy, I was given a clean bill of health. The original plan included pinpoint radiation but after consulting the tumor board, my oncologist told me the group decision was to stop with chemo. Now I could plan my wedding and get on with my life. My oncologist and nurse even attended my wedding. Years later at a follow up, my oncologist told me that we dodged a bullet by not doing the radiation as many patients were now being diagnosed with leukemia or breast cancer. I remember feeling a cold shiver at the thought that I could have been in that position. We were blessed with a daughter even though I had been told I most likely would be sterile. Fast forward to 2017, I had a cold early in the year but could not shake the cough. I was given a couple of rounds of antibiotics, then was referred to the pulmonologist. I had a thoracentisis. The pulmonologist told me not to Google, but I did, not about pleural effusions but about long term effects of MOPP ABVD. The following week, he gave me the diagnosis and I admitted my transgression. Maybe the lung cancer is just the hand that I was dealt, but I can't help but tie it back to the treatment for Hodgkins. I have been very fortunate to have wonderful support from my family, friends, and co-workers. I have also had incredible medical care from physicians, nurses, and support staff. If any Hodgkins survivors who only had chemo and have also been diagnosed with lung cancer reach out to me, I would love to correspond and discuss histories. Thanks for reading my story.
  25. Here is the weekly clip report: MONDAY, MAY 8 Medical Xpress “Study Identifies New Target to Fight Prostate, Lung Cancer” https://medicalxpress.com/news/2017-05-prostate-lung-cancer.html WTIU-FM (Indiana Public Media) “New Study To Examine Why Patients Choose Lung Cancer Screenings” http://indianapublicmedia.org/news/study-examine-patients-choose-lung-cancer-screenings-119528/ Cancer Network “Checkpoint Inhibitors Improve Response to Salvage Chemotherapy in NSCLC” http://www.cancernetwork.com/lung-cancer/checkpoint-inhibitors-improve-response-salvage-chemotherapy-nsclc TUESDAY, MAY 9 US News & World Report “Here’s How to Manage Lung Cancer Side Effects” http://health.usnews.com/health-care/patient-advice/articles/2017-05-09/heres-how-to-manage-lung-cancer-side-effects New York Post “How Assembling the Right Cancer Team May Save Your Life” http://nypost.com/2017/05/09/how-assembling-the-right-cancer-team-may-save-your-life/ WEDNESDAY, MAY 10 WETA-TV (PBS—Washington, DC) “This Cuban Lung Cancer Drug Is Giving Some U.S. Patients Hope” http://www.pbs.org/newshour/bb/cuban-lung-cancer-drug-giving-u-s-patients-hope/ Cure “Will Immunotherapy Move into All Lung Cancer Patient Populations?” http://www.curetoday.com/articles/will-immunotherapy-move-into-all-lung-cancer-patient-populations THURSDAY, MAY 11 Lung Cancer News Today “Clinical Trial to Test Biocept’s Target Selector Platform as Diagnosis, Monitoring Tool for Lung Cancer” https://lungcancernewstoday.com/2017/05/11/lung-cancer-platform-target-selector-developed-biocept-undergo-clinical-trial/ Reuters “U.S. FDA Approves Merck Immunotherapy/Chemo Combo for Lung Cancer” http://www.reuters.com/article/us-merck-co-lungcancer-idUSKBN1862Y2 FRIDAY, MAY 12 Fortune “Why Merck’s Keytruda Just Became a Lung Cancer Game Changer” http://fortune.com/2017/05/11/fda-lung-cancer-merck-keytruda/ Cancer Therapy Advisor “Alectinib Beats Crizotinib in ALK-positive Non-small Cell Lung Cancer” http://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-alectinib-crizotinib-compare-treatment/article/661354/ Eurek Alert “Invasive Lung Cancer Cells Display Symbiosis -- Key to metastasis” https://www.eurekalert.org/pub_releases/2017-05/ehs-ilc050917.php Reuters “AstraZeneca’s Durvalumab Shown in Trial to Reduce Risk of Death from Lung Cancer” http://www.reuters.com/article/astrazeneca-cancer-idUSFWN1IE06Z
×